How Glucosamine Supplements May Raise Dementia Risk in People With Early Memory Problems

# Why this matters

# What the researchers found Researchers analyzed more than 65,000 patient records, including roughly 24,000 people with dementia and 41,000 with MCI. In the subgroup with MCI, those taking glucosamine were 25% more likely to progress to full clinical dementia. In people already diagnosed with Alzheimer's or other dementias, regular glucosamine use was associated with a 25% higher five-year mortality.

The team also examined post-mortem brains and found elevated, abnormal glycan structures—dense sugar coatings on proteins—in Alzheimer's patients compared with age-matched controls. In genetically modified mouse models of Alzheimer's disease, adding glucosamine exacerbated memory impairment. Blocking the enzymes that synthesize these glycans reversed cognitive deficits in those animal experiments.

# The proposed biological mechanism Glucosamine is an amino sugar that crosses the blood-brain barrier and feeds into cellular glycosylation pathways. Glycosylation attaches branched sugar chains (glycans) to newly made proteins. Under normal conditions this helps proteins fold, move, and signal properly. In Alzheimer's brains, the researchers observed a global increase in abnormal glycan structures, a phenomenon the study describes as protein hyperglycosylation.

When brain metabolism is already impaired—what some researchers term a localized metabolic failure or "type 3 diabetes"—extra glucosamine appears to provide substrate that accelerates hyper-tagging of proteins. Those over-tagged proteins misfold, aggregate, and trigger neurotoxic inflammation, which can accelerate neurodegeneration.

# How this compares with earlier studies Previous population-based observational studies reported that regular glucosamine use in cognitively healthy adults sometimes correlated with reduced systemic inflammation and lower dementia risk. The University of Florida work differs by focusing on people with existing cognitive decline and by adding tissue- and animal-level evidence that glucosamine can worsen pathology in metabolically compromised brains.

# Practical implications for readers If you or a family member has mild cognitive impairment or a dementia diagnosis, discuss glucosamine use with your clinician. The new evidence suggests that a supplement that may be benign or beneficial in otherwise healthy adults could have harmful effects when brain metabolism is already altered. Clinicians and patients must weigh joint symptom management options and consider alternatives that do not supply extra amino sugar to the central nervous system.

# What remains unsettled The UF paper integrates population, tissue, and animal data but does not by itself establish definitive cause-effect in humans across all settings. The study authors and independent reviewers have called for clinical trials and further mechanistic work to confirm whether stopping or avoiding glucosamine alters dementia trajectories in people with MCI.

# Bottom line Glucosamine can cross into the brain and fuel biochemical pathways that are already dysregulated in Alzheimer's. For people with early memory problems, regular glucosamine use was associated with a meaningful increase in risk of progressing to dementia in this study. Talk to your healthcare provider before continuing or starting glucosamine if cognitive decline is present.